Abstract Title:

Sulforaphane inhibits osteoclastogenesis by inhibiting nuclear factor-kappaB.

Abstract Source:

Mol Cells. 2005 Dec 31;20(3):364-70. PMID: 16404151

Abstract Author(s):

Soo-Jin Kim, So-Young Kang, Hyun-Hee Shin, Hye-Seon Choi

Article Affiliation:

Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan, Ulsan 680-749, Korea.

Abstract:

We show that sulforaphane inhibits osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-kB ligand (RANKL) in osteoclast (OC) precursors. Sulforaphane, an aliphatic isothiocyanate, is a known cancer chemo-preventative agent with anti-oxidative properties. Nuclear factor-kB (NF-kB) is a critical transcription factor in RANKL-induced osteoclastogenesis, and electrophoretic mobility shift assays (EMSAs) and assay of NF-kB-mediated secreted alkaline phosphatase (SEAP) revealed that sulforaphane selectively inhibited NF-kappaB activation induced by RANKL. Inhibition may involve interaction of sulforaphane with thiol groups, since it was prevented by reducing agents.

Study Type : In Vitro Study

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.